[go: up one dir, main page]

WO2002066477A3 - Imidazopyridines - Google Patents

Imidazopyridines Download PDF

Info

Publication number
WO2002066477A3
WO2002066477A3 PCT/GB2002/000634 GB0200634W WO02066477A3 WO 2002066477 A3 WO2002066477 A3 WO 2002066477A3 GB 0200634 W GB0200634 W GB 0200634W WO 02066477 A3 WO02066477 A3 WO 02066477A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
compound
relates
present
imidazopyridines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/000634
Other languages
French (fr)
Other versions
WO2002066477A2 (en
Inventor
Alexander Graham Dossetter
Peter Kenny
Darren Mckerrecher
Michael Wardleworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Priority to AU2002229976A priority Critical patent/AU2002229976A1/en
Publication of WO2002066477A2 publication Critical patent/WO2002066477A2/en
Publication of WO2002066477A3 publication Critical patent/WO2002066477A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds wherein: - R1, R2 and R3 are as defined in the description; and ring A is optionally further substituted.
PCT/GB2002/000634 2001-02-20 2002-02-15 Imidazopyridines Ceased WO2002066477A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002229976A AU2002229976A1 (en) 2001-02-20 2002-02-15 Imidazopyridines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100567-7 2001-02-20
SE0100567A SE0100567D0 (en) 2001-02-20 2001-02-20 Compounds

Publications (2)

Publication Number Publication Date
WO2002066477A2 WO2002066477A2 (en) 2002-08-29
WO2002066477A3 true WO2002066477A3 (en) 2002-10-17

Family

ID=20283057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000634 Ceased WO2002066477A2 (en) 2001-02-20 2002-02-15 Imidazopyridines

Country Status (3)

Country Link
AU (1) AU2002229976A1 (en)
SE (1) SE0100567D0 (en)
WO (1) WO2002066477A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10246890A1 (en) * 2002-10-08 2004-04-22 Grünenthal GmbH New C-(imidazo-(1,2-a)-pyridin-3-yl)-methylamines, are nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, septic shock, neurodegenerative diseases, inflammatory pain or cancer
DE10247271A1 (en) * 2002-10-10 2004-08-26 Grünenthal GmbH Use of new and known 7-(methyl or trifluoromethyl)-imidazo-(1,2-a)-pyridines as nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, neurodegenerative diseases, inflammatory pain, diabetes or cancer
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7148353B2 (en) 2003-10-28 2006-12-12 Sepracor Inc. Imidazo[1,2-a] pyridine anxiolytics
GB0403781D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical compounds
MX2007000481A (en) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Methods for treating hepatitis c.
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (en) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Thienopyridine for treating hepatitis C
WO2007069565A1 (en) 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
RU2008143179A (en) * 2006-03-31 2010-05-10 Новартис АГ (CH) ORGANIC COMPOUNDS
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
WO2008032764A1 (en) 2006-09-13 2008-03-20 Kyowa Hakko Kirin Co., Ltd. Fused heterocyclic derivative
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CA2672213C (en) 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
CN103214482B (en) 2007-04-03 2016-06-29 阵列生物制药公司 Imidazo [1,2-a] pyridine compounds as receptor tyrosine kinase inhibitors
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
CN101903381A (en) * 2007-10-24 2010-12-01 日本医事物理股份有限公司 New compound with affinity for amyloid
EP2300470A2 (en) * 2008-05-19 2011-03-30 Sepracor Inc. Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JP5931752B2 (en) 2011-02-01 2016-06-08 協和発酵キリン株式会社 Fused heterocyclic derivatives
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
TW201410677A (en) 2012-07-31 2014-03-16 Kyowa Hakko Kirin Co Ltd Condensed ring heterocyclic compound
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
TW201718581A (en) 2015-10-19 2017-06-01 英塞特公司 Heterocyclic compounds as immunomodulators
LT3377488T (en) 2015-11-19 2023-01-10 Incyte Corporation HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US9926316B2 (en) 2016-03-03 2018-03-27 The Cleveland Clinic Foundation Antitumor derivatives for differentiation therapy
MA44860A (en) 2016-05-06 2019-03-13 Incyte Holdings Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
CN116115764A (en) 2016-12-22 2023-05-16 因赛特公司 Tetrahydroimidazo[4,5-C]pyridine derivatives as PD-L1 internalization inducers
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
JP7303108B2 (en) 2016-12-22 2023-07-04 インサイト・コーポレイション Bicyclic heteroaromatic compounds as immunomodulators
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
ES3030010T3 (en) 2018-03-30 2025-06-26 Incyte Corp Heterocyclic compounds as immunomodulators
BR112020022936A2 (en) 2018-05-11 2021-02-02 Incyte Corporation tetrahydro-imidazo [4,5-c] pyridine derivatives as pd-l1 immunomodulators
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
JP2023500395A (en) 2019-11-11 2023-01-05 インサイト・コーポレイション Salts and Crystal Forms of PD-1/PD-L1 Inhibitors
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
TW202233616A (en) 2020-11-06 2022-09-01 美商英塞特公司 Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN113666926A (en) * 2021-09-08 2021-11-19 桂林理工大学 A Facile Michal Addition of 2-phenylimidazo[1,2-a]pyridine to Chalcone

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019953A2 (en) * 1995-11-28 1997-06-05 Asta Medica Aktiengesellschaft New lh-rh antagonists with improved effectiveness
WO1998003505A2 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
WO1999020223A2 (en) * 1997-10-20 1999-04-29 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
WO1999041252A1 (en) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999041251A1 (en) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019953A2 (en) * 1995-11-28 1997-06-05 Asta Medica Aktiengesellschaft New lh-rh antagonists with improved effectiveness
WO1998003505A2 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
WO1999020223A2 (en) * 1997-10-20 1999-04-29 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
WO1999041252A1 (en) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999041251A1 (en) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAMINSKI J J ET AL: "JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 28, no. 7, 1985, pages 876 - 892, XP002094814, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Also Published As

Publication number Publication date
AU2002229976A1 (en) 2002-09-04
SE0100567D0 (en) 2001-02-20
WO2002066477A2 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
WO2002066477A3 (en) Imidazopyridines
SE0100568D0 (en) Compounds
WO2003082853A8 (en) New compounds
MXPA04005209A (en) ADENOSINE A ??2a? RECEPTOR ANTAGONISTS.
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
SE0100566D0 (en) Compounds
TW200745111A (en) New compounds
WO2004037789A8 (en) Methylene urea derivatives as raf-kinase inhibitors
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2005077950A3 (en) Medicaments with hm74a receptor activity
WO2002065979A3 (en) (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
MXPA05011076A (en) Chemical compounds.
MXPA04003192A (en) Succinic acid salts of 5, 8, 14-triazatetracyclo '10.3.1.0 <2,11>.0<4,9> -hexadeca -2(11), 3, 5, 7, 9-pentaene and pharmaceutical compositions thereof.
MXPA04002338A (en) Carbazole derivatives and their use as npy5 receptor antagonists.
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2004032826A3 (en) Process for preparing tannate tablet capsule or other solid dosage forms
SE0102440D0 (en) New compound
MXPA04000779A (en) Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease.
WO2002000166A3 (en) New compounds useful as antibacterial agents
WO2003047505A3 (en) Topoisomerase poison agents
NO20044531L (en) Imidazolinylmethyl-aralkylsulfonamides, compositions comprising such, processes for the preparation thereof, such compounds as medicaments and the use of such compounds for the manufacture of medicaments for the treatment of disease
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
WO2002092565A3 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP